Fig. 5.

Meta-analyses of post-treatment differences in postprandial glucose (mg/dL) between insulin aspart 30/70 and (a) long-acting insulin analogues[30–32] and (b) biphasic human insulin.[33–35] Reproduced from Qayyum et al.[28]